• Traverse
    • Timmerman Traverse for LSC 2025
    • Past Climbs (2018-2025)
  • Speaking
  • About
    • Community
    • Frontpoints
    • Podcast
    • Events
    • Advisors
    • Team
      • David Shaywitz
      • Alex Harding
      • Pedro Rafael Rosado
      • Steve White
    • Hood Biography
    • In the News
    • Testimonials
  • Contact
  • Subscribe
    • Individual Subscriptions
    • Group Subscriptions
Biotech Leaders Get It
  • Traverse
    • Timmerman Traverse for LSC 2025
    • Past Climbs (2018-2025)
  • Speaking
  • About
    • Community
    • Frontpoints
    • Podcast
    • Events
    • Advisors
    • Team
      • David Shaywitz
      • Alex Harding
      • Pedro Rafael Rosado
      • Steve White
    • Hood Biography
    • In the News
    • Testimonials
  • Contact
  • Subscribe
    • Individual Subscriptions
    • Group Subscriptions
16
Nov
2015

Rewriting Pharma’s Broken Social Contract: Q&A with Alnylam’s John Maraganore

/
Luke Timmerman
/
8
/
All, Politics, The Edge
16 Nov 2015

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
13
Nov
2015

Pfizer Sizes Up Young Gun, CRISPR in the Spotlight & More Bad Behavior

/
Luke Timmerman
/
0
/
All
13 Nov 2015

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
10
Nov
2015

Pursuing a Hard Cancer Target: Q&A With Warp Drive CEO Laurence Reid

/
Luke Timmerman
/
1
/
All, Cancer, Drugs
10 Nov 2015

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
9
Nov
2015

Raiding the Talent at Pfizer: Where Might The R&D Brains Go?

/
Luke Timmerman
/
3
/
All, Drugs, People, The Edge
09 Nov 2015

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
6
Nov
2015

D.C. Crosshairs on Pharma, ASH Roller Coaster & An IPO Cooldown

/
Luke Timmerman
/
0
/
All, Drugs, Politics
06 Nov 2015

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
2
Nov
2015

The $100M Club: See Who Makes the Cut in SF, Boston, and Beyond

/
Luke Timmerman
/
2
/
All, People, The Edge
02 Nov 2015

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
30
Oct
2015

Pfizer’s New MegaMerger Target, Valeant Burns & Amgen’s Cancer Advance

/
Luke Timmerman
/
0
/
All, Drugs
30 Oct 2015

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
27
Oct
2015

See the Photos From the TR1000 Party in SF

/
Luke Timmerman
/
1
/
All, People
27 Oct 2015

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
26
Oct
2015

Biotech Should Give More Young People a Chance

/
Luke Timmerman
/
14
/
All, People, The Edge
26 Oct 2015

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
23
Oct
2015

Investors Shouldn’t Nitpick Old Data. Bluebird’s New Gene Therapy Vector Makes a Difference

/
Zachary Fink
/
1
/
All, Drugs
23 Oct 2015

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
23
Oct
2015

Valeant’s Takedown, FDA Black Boxes & the Cancer Vaccine Scramble

/
Luke Timmerman
/
0
/
All
23 Oct 2015

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
19
Oct
2015

Playing Hardball: Academia Looks to Even the Score with VCs, Big Pharma

/
Luke Timmerman
/
1
/
All, The Edge
19 Oct 2015

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
16
Oct
2015

Theranos Exposed, Lilly Cholesterol Drug Flops & 23andMe Raises More Dough

/
Luke Timmerman
/
0
/
All, Drugs
16 Oct 2015

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
14
Oct
2015

Introducing Signal: The Stat Podcast I’m Co-Hosting With Meg Tirrell

/
Luke Timmerman
/
1
/
All
14 Oct 2015

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
12
Oct
2015

Who Deserves To Be Called a Founder, and Who Doesn’t?

/
Luke Timmerman
/
4
/
All, People, The Edge
12 Oct 2015

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
9
Oct
2015

Vertex Takes Heat, Valeant Takes Even More, and Express Scripts Cuts a Deal

/
Luke Timmerman
/
2
/
All, Strategy
09 Oct 2015

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
5
Oct
2015

GlaxoSmithKline: A Bunch of Bozos, Or Crazy Like a Fox?

/
Luke Timmerman
/
4
/
All, Strategy, The Edge
05 Oct 2015

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
2
Oct
2015

The Immune System as a Metaphor for the Turing Pharma Mess

/
Kyle Serikawa
/
0
/
All, Drugs
02 Oct 2015

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
2
Oct
2015

Fallout from the Drug Pricing Fiasco, the New Thing in Genome Editing & More

/
Luke Timmerman
/
0
/
All, Cancer
02 Oct 2015

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
1
Oct
2015

The Next Macro (Phage) Thing in Immuno-Oncology

/
Luke Timmerman
/
2
/
All, Cancer, Drugs
01 Oct 2015

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
‹ Previous 1 … 72 73 74 75 76 … 79 Next ›

Get In-depth Biotech Coverage with Timmerman Report.

Individual Subscription

Group Subscription

Or: Sign in to your account

Your account

Sign in

What Readers Are Saying

testimonial
testimonial
testimonial

View More Testimonials ➛

Twitter

Tweets by ldtimmerman Follow @ldtimmerman
© Copyright 2025, TimmermanReport.com
Privacy Policy | Terms of Use
Custom WordPress site by: Perception Builder